A Phase 3, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 3, Multicenter, Open-label, Long-term Study of SYR-472 (25 mg) in Patients With Type 2 Diabetes Mellitus Complicated by Severe Renal Impairment or End-stage Renal Disease
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 107 participants.
Also called NCT02512068
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 107 participants
- Sponsor
- Registry
-
NCT02512068 -
U1111-1172-1511
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT02512068. Randomized; quadruple masking; primary purpose treatment. Start 2015-08-07 (actual); primary completion 2018-04-24 (actual). Results posted on 2019-11-04.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase 3, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 3, Multicenter, Open-label, Long-term Study of SYR-472 (25 mg) in Patients With Type 2 Diabetes Mellitus Complicated by Severe Renal Impairment or End-stage Renal Disease
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Trelagliptin 25 mg
- Intervention (Drug)
- Placebo
- Lead sponsor
- Takeda
Record details
- Record id
cardio:ct-nct02512068- Content hash
529123ec71716f995fd995ce7c128c95126d0e6a01a085f057d18dcd7b78f182